期刊文献+

非小细胞肺癌EGFR基因突变与ERCC1、RRM1、TUBB3 mRNA表达相关性研究 被引量:3

Association of EGFR mutation with the mRNA expression of ERCC1,RRM1 and TUBB in non-small cell lung cancer tissues
下载PDF
导出
摘要 目的:探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)患者表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变与切除修复交叉互补蛋白1(excision repair crosscomplementation 1,ERCC1)、核苷酸还原酶亚单位M1(ribonucleotide reductase subunit M1,RRM1)及3型β-微管蛋白基因(classⅢβ-tubulin,TUBB3)表达的关系。方法:回顾性分析我院经病理诊断的69例NSCLC患者的手术切除的肿瘤标本,利用扩增受阻突变系统(amplification refractory mutation system,ARMS)进行EGFR基因突变检测,应用实时荧光定量PCR检测ERCC1、RRM1及TUBB3mRNA的表达水平。结果:69例患者中,EGFR突变率为33.33%(23/69),在性别、吸烟史、病理类型组间突变率有显著性差异。ERCC1低、高表达率分别为59.42%(41/69)、40.58%(28/69),EGFR突变与ERCC1表达呈负相关性,EGFR无突变时ERCC1趋向于高表达(P=0.024);RRM1低、高表达率分别为31.88%(22/69)、68.12%(47/69),EGFR突变与RRM1表达无相关性(P>0.05);TUBB3低、高表达率分别为8.70%(6/69)、91.30%(63/69),EGFR突变与TUBB3表达无相关性(P>0.05)。ERCC1、RRM1、TUBB3三者间的基因表达均无相关性。结论:NSCLC患者肿瘤组织中EGFR突变患者ERCC1倾向低表达,这类患者可能更能从铂类化疗和靶向药物中受益。 Objective:To better understand the correlation between EGFR mutation and the expression of several biomarkers,including ERCCl,RRM1,TUBB3.Methods:A total of 69 NSCLC cases were analyzed concurrently for EGFR mutations and mRNA expression of the ERCCl,RRM1,TUBB3 genes.EGFR mutation was detected by amplified refractory mutation system(ARMS),mRNA expression of the ERCCl,RRM1,TUBB3 genes were detected by real time polymerase chain reaction analysis(RT-PCR).Results:Among the 69 NSCLC cases screened for this study EGFR mutation rate was found in 33.33%(23/69),there was a significant difference in gender,smoking status,histology.The low and high mRNA levels of ERCC1 were 59.42%(41/69) and 40.58%(28/69),respectively.EGFR mutation expression was negative correlation with ERCC1 expression(P=0.024).The low and high expression rates of RRMl were 31.88%(22/69),68.12%(47/69),respectively.EGFR mutation was not correlation with the expression of RRMl(P0.05);the low and high expression rates of TUBB3 were8.70%(6/69),91.30%(63/69) respectively.There was no significant correlation between EGFR mutation and the expression of TUBB3(P0.05).Also there was no relationship among the expressions of ERCC1,RRMl and TUBB3.Conclusion:Low ERCC1 expression is more likely to be expressed with EGFR mutation in NSCLC,who may benefit from the platinum-based chemotherapy and TKI.
出处 《临床与病理杂志》 2016年第1期55-60,共6页 Journal of Clinical and Pathological Research
关键词 非小细胞肺癌 表皮生长因子受体 切除修复交叉互补蛋白1 3型β-微管蛋白基因 分子检测 non-small cell lung cancer(NSCLC) epidermal growth factor receptor(EGFR) excision repair crosscomplementation 1(ERCC1) ribonucleotide reductase subunit Ml(RRM1) class Ⅲ β-tubulin(TUBB3) molecular detection
  • 相关文献

参考文献15

  • 1Siegel R, MaJ, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29.
  • 2张建海,张艳丽.PTEN与非小细胞肺癌临床病理特征及预后的相关性[J].中国医药导报,2013,10(1):98-100. 被引量:10
  • 3Santos ES, Blaya M, Raez LE. Gene expression profiling and non- small-cell lung cancer: where are we now? [J]. Clin Lung Cancer, 2009, 10(3): 168-173.
  • 4Schuler M, Fischer JR, Groh6 C, et al. Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib[J].Oncologist, 2014, 19(10): 1100-1109.
  • 5Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. Lancet Oncol, 2012, 13(3):239-246.
  • 6Fukihara J, Watanabe N, Taniguchi H, et al. Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR- mutant non-small cell lung cancer[J]. Oncology, 2014, 86(2): 86-93.
  • 7Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med, 2009, 361(10): 947-957.
  • 8Koh Y, Jang B, Han SW, et al. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resectednon-smaU cell lung cancer[J].J Thorac Oncol, 2010, 5(3): 320-325.
  • 9Joerger M, deJoug D, Burylo A, et al. Tubulin, BRCA1, ERCCI, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy[J]. Lung Cancer, 2011, 74(2): 310-317.
  • 10Wu YL, Zhong WZ, Li LY, et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small celllung cancer: a meta-analysis based on updated individual patient data from six medical centers in China's Mainland[J]. J Thorac Oncol, 2007, 2(5): 430-439.

二级参考文献19

  • 1刘玉环,王锡智,蔡在龙,俞超芹,崔英,沙金燕.PTEN基因突变与遗传性癌症综合征及其相关疾病的研究进展[J].第二军医大学学报,2005,26(1):90-92. 被引量:5
  • 2李英红,徐春林,李慧慧.PTEN在非小细胞肺癌中的表达及其临床意义[J].哈尔滨医科大学学报,2006,40(5):394-396. 被引量:7
  • 3Jemal A,Siegel R,Xu JQ, et al. Cancer statistics[J].CA Cancer J Clin,2010,60(5) :1-24.
  • 4Paz-Ares L, Soulires D, Melezinek I, et al. Clinical outcomes in non- small-cell lung cancer patients with EGFR mutations: pooled analysis [J].J Cell Mol Med,2010,14(1 2):51-69.
  • 5Zhou C,Wu YL,Chen G,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation- positive non-small-cell lung cancer (OPTIMAL,CTONG-0802) : a multicentre,open-label, randomised, phase 3 study[J]. Lancet Oncol,2011,12(8) :735 -742.
  • 6Kalikaki A, Kanaki M, Vassalou H, et al. DNA repair gene polymor phisms predict favorable dinicaI outcome in advanced non-small cell lung cater[J]. Clin Lung Cancer,2009,10(2) : 118-123.
  • 7Roth JA,Carlson JJ. Prognostic role of ERCC1 in advanced non small-cell lung cancer: A systematic review and meta-analysis [J]. Clin Lung Cancer,2011,12(6):393 -401.
  • 8Lee KH, Min HS, Han SW, et al. ERCC1 expression by immuno- histoehemistry and EGFR mutations in resected non small cell lung eaneer[J]. Lung Cancer, 2008,60(3):401-407.
  • 9Gandara DR, Grimminger P, Mack PC, et al. Association of epi dermal growth factor receptor activating mutations with low ER- CC1 gene expression in non-small cell lung eaneer[J]. Thorae Oncol,2010,5(12) :1933-1938.
  • 10Taron M,Rosell R,Felip E,et al. BRCA1 mRNA expression lev- els as an indicator of chemoresistance in lung cancer[J]. Hum Mol Genet,2004,13(20) :2443 -2449.

共引文献13

同被引文献22

引证文献3

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部